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for rehabilitation were a27 (a1 %), for occupational therapy a14 (a1 %). Costs for 
sick leave payments came to a247 (5%) in 2006. Costs increase when a patient had 
an inpatient episode. A patient with at least one inpatient visit causes average annual 
costs of a15,487 (inpatient: a12,938; medication: a1552; outpatient: a322; rehabilita-
tion: a108; occupational therapy: a16; sick leave payments: a551). A total of 2602 
(23 %) patients had at least one inpatient visit in 2006. CONCLUSIONS: The 
major cost driver in schizophrenia from a health insurance perspective in Germany is 
inpatient care as well as to a lesser extent medication costs. Patients with at least 
one inpatient episode cause threefold cost compared with the average cost of 
schizophrenia.
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OBJECTIVES: To identify direct and indirect costs associated with adult ADHD. 
METHODS: An analysis of health care claims databases (MarketScan) identiﬁed 
adults (aged q 18) diagnosed with ADHD q 2 times within a 12-month period between 
2002 and 2007, and with q1 diagnosis of ADHD or an ADHD-related prescription 
claim in 2006. Control patients with no diagnosis of ADHD were randomly matched 
3:1 to ADHD patients based on gender, age, region, and presence of capitated services. 
Direct health care costs were based on inpatient visits, ER visits, outpatient services 
and visits, and prescriptions. Indirect costs included work absences (WA), short- 
term disability (STD), and worker’s compensation (WC). Comorbidity was assessed 
through the Deyo-Charlson Comorbidity Index (CCI) and the presence of speciﬁc 
nonpsychiatric and psychiatric comorbidities known to be associated with ADHD 
from the medical literature. RESULTS: A total of 31,752 ADHD patients and 95,256 
controls were identiﬁed. Compared with controls, ADHD patients had higher mean 
costs associated with health care ($4306 vs. $2418, P  0.0001) and STD ($743 vs. 
$424, P  0.0001). There were no signiﬁcant differences in mean costs associated with 
WA ($3304 vs. $3404, P  0.5686) or WC ($356 vs. $380, P  0.8689). Although 
the absolute difference was small, the mean CCI was signiﬁcantly lower for ADHD 
patients than for controls (0.15 vs. 0.18, P  0.0001). Compared with controls, ADHD 
patients were more frequently diagnosed with most of the comorbidities investigated. 
The top 3 diagnoses with the largest differences in cohort comorbidity rates were 
injuries, depression, and bipolar disorder (P  0.0001). CONCLUSIONS: Patients 
with ADHD had medical expenditures almost twice as high as patients without ADHD 
and were more likely to seek medical care for injuries. Given a 4.4% prevalence rate 
of adult ADHD in the United States, the overall societal and direct medical costs for 
adult ADHD may be signiﬁcant. Supported by funding from Shire Development Inc.
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OBJECTIVES: To analyze treatment patterns and costs following ﬁrst-line treatment 
of major depressive disorder (MDD). METHODS: Using a retrospective cohort design 
and claims data (January 2003-March 2008), we examined patients who began ﬁrst-
line monotherapy for MDD, and followed them for 1 year through successive lines of 
therapy. Patients had: at least 1 health care claim due to MDD between January 2004 
and March 2007; initiated MDD monotherapy within 7 days of ﬁrst MDD diagnosis 
(index date); no previous exposure to index monotherapy in the 180 days prior to 
index date; continuous enrollment 6 months prior to and 12 months post index date. 
The adjusted average weekly health care cost attributable to mental health problems 
was compared across lines of treatment using 2-part regression models with log 
transformation of costs. RESULTS: A total of 14,601 patients were identiﬁed. Selec-
tive serotonin reuptake inhibitors were the leading treatment choice across ﬁrst, 
second, and third lines of therapy, followed by benzodiazepines, buproprion, and 
serotonin-noradrenaline reuptake inhibitors. Patients either continued with their index 
treatment (6.7%), added a new therapy (27.2%), switched to another therapy 
(59.1%), or discontinued treatment (7.1%). Of the 12,597 patients who added or 
switched therapy, 5714 received third-line therapy, and of these, 2227 progressed to 
fourth-line therapy within the ﬁrst year. Average weekly costs for patients initiating 
1, 2 and 3 lines of therapy were $70, $68, and $95, respectively. Patients still not 
achieving an adequate response during fourth-line therapy incurred between $143 and 
$334 per week in health care costs. Patients who switched or added another therapy 
generally incurred the highest costs. CONCLUSIONS: Patients with MDD who do 
not respond to successive lines of treatment incur higher mental health costs than 
responsive patients. This pattern is particularly evident between second and third, and 
between third and fourth lines of treatment. Supported by funding from AstraZeneca 
Pharmaceuticals LP.
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OBJECTIVES: To carry-out a 6-month cost-effectiveness analysis (CEA) of the effect 
of Pregabalin (PGB) versus Usual Care (UC) in Duloxetine-refractory out-patients with 
Generalized Anxiety Disorder (GAD) treated according with usual medical practice in 
Mental Health Centers in Spain. METHODS: This CEA used secondary data extracted 
from a 6-month cohort prospective observational study (the ADAN study) designed 
to ascertain cost and health care resources utilization in subjects with GAD (DSM-IV 
criteria). Duloxetine-refractory subjects were deﬁned as those who claimed of persis-
tent symptoms of anxiety and showed suboptimal response (HAM-Anxiety scale q 16) 
after a course of standard doses of duloxetine for 6 month. At baseline, patients could 
switch to PGB, monotherapy or add-on, or to UC which could include ISRS/ISRN/
other antidepressants, benzodiazepine, anti-epileptics different than PGB or a combi-
nation. Health outcomes included quality-adjusted life years (QALYs) gain by EQ-5D 
questionnaire. The perspective of CEA was that of a 3rd-payer in year 2009. Sensitivity 
analysis was performed by means of bootstrapping techniques (10000 re-samples were 
obtained) in order to obtain a cost-effectiveness acceptability curve. RESULTS: A total 
of 132 duloxetin-refractory subjects (mean baseline HAM-A; 25.6 pts) were identiﬁed; 
103 and 29 in the PGB and UC groups, respectively. Compared with UC, PGB therapy 
was associated with signiﬁcant QALY gain after 6 months of treatment; 0.1191 o 
0.1163 vs 0.0810 o 0.0777, p  0.043, but higher health care costs; a1,402.1 o 849.1 
vs a1,051.5 o 789.1, p  0.048. The deterministic ICER ratio was a9,210 per QALY 
gained with a re-sampling ICER of a11,234 (95 CI: 1,591–20,877). The 90% of re-
samples fold below a20,513 threshold and 95% below a29,901. CONCLUSIONS: 
Despite the small sample and observational design, this evaluation could suggest that 
pregabalin may be cost-effective in comparison with usual care in duloxetine-refrac-
tory subjects with Generalized Anxiety Disorders managed in Mental Health Centers 
under usual medical practice in Spain.
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OBJECTIVES: To carry-out a 6-month cost-effectiveness analysis (CEA) of the effect 
of Pregabalin (PGB) versus ISRS/ISRN in benzodiazepine refractory out-patients with 
Generalized Anxiety Disorder (GAD) treated according with usual medical practice in 
Mental Health Centers in Spain. METHODS: This CEA used secondary data extracted 
from a 6-month cohort prospective observational study (the ADAN study) designed 
to ascertain cost and health care resources utilization in subjects with GAD (DSM-IV 
criteria). Benzodiazepine-refractory subjects were deﬁned as those who claimed of 
persistent symptoms of anxiety and showed suboptimal response (HAM-Anxiety scale 
 16) after a course of standard doses of benzodiazepines, alone or in combination, 
for 6 months. At baseline, patients could switch to PGB monotherapy or add-on or 
to ISRS/ISRN along or in combination. Outcomes included quality-adjusted life years 
(QALYs) gain using the EQ-5D questionnaire. As the perspective of CEA was that of 
a 3rd-payer, only health care resources use and corresponding costs were computed 
in year 2009. Sensitivity analysis was performed by means of bootstrapping techniques 
(10000 re-samples were obtained) in order to obtain a cost-effectiveness acceptability 
curve. RESULTS: A total of 231 benzodiazepine-refractory subjects (mean baseline 
HAM-A; 25.1 pts) were identiﬁed; 116 in the PGB and 115 in the ISRS/ISRN group, 
respectively. Compared with ISRS/ISRN, PGB therapy was associated with higher 
QALY gain; 0.1126 o 0.09857 vs. 0.1008 o 0.09460, but increased health care costs; 
a998.1 o 691.5 vs. a894.2 o 648.5. The deterministic ICER ratio was a8,89 per QALY 
gained with a re-sampling ICER of a6,214 (95 CI: 1,825–10,604). The 90% of re-
samples fold below a26,556 threshold and 92% below a30,000. CONCLUSIONS: 
Despite the observational design of the primary study, this evaluation could suggest 
that pregabalin may be cost-effective in comparison with ISRS/ISRN in benzodiazepine 
refractory out-patients with Generalized Anxiety Disorders managed in Mental Health 
Centers under usual medical practice in Spain.
